Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.39 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 2/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | ICMT | O60725 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020191 | 1.00 | MGLL (0.42) | MGLLGCGRNR5A2NR5A1TLR8 | |
| SCHEMBL1022266 | 0.87 | LMNA (0.34) | MGLL | |
| SCHEMBL1022267 | 0.87 | LMNA (0.34) | MGLL | |
| SCHEMBL1020231 | 0.84 | GCGR (0.36) | GCGRTLR8 | |
| SCHEMBL1020229 | 0.84 | GCGR (0.36) | GCGRTLR8 | |
| SCHEMBL1021311 | 0.84 | GCGR (0.38) | GCGRNR5A2NR5A1NPC1RAB9A | |
| SCHEMBL1021312 | 0.84 | GCGR (0.38) | GCGRNR5A2NR5A1NPC1RAB9A | |
| SCHEMBL1019259 | 0.84 | GCGR (0.40) | MGLLGCGRPTGS1PTGS2 | |
| SCHEMBL1019258 | 0.84 | GCGR (0.40) | MGLLGCGRPTGS1PTGS2 | |
| SCHEMBL1022421 | 0.82 | LMNA (0.35) | TLR8NPC1RAB9AICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013187-B2 | 2-cyclopenten-1-one oxime derivatives inhibiting production of TNF-α | AMOREPACIFIC CORPORATION (KR) | 2011-09-06 | — | — | US | claimed |
| EP-1841729-B1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORP (KR) | 2011-01-12 | — | — | EP | claimed |
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | AMOREPACIFIC CORPORATION (KR) | 2009-02-05 | — | — | US | claimed |
| US-8013187-B2 | 2-cyclopenten-1-one oxime derivatives inhibiting production of TNF-α | AMOREPACIFIC CORPORATION (KR) | 2011-09-06 | — | — | US | disclosed |
| EP-1841729-B1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORP (KR) | 2011-01-12 | — | — | EP | disclosed |
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | AMOREPACIFIC CORPORATION (KR) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | TNF, PDE4A, PDE3B | MGLL 3774/4885GCGR 2868/4885NR5A2 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.